Ciliary Body and Choroid Melanoma, Small Size
6
0
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
16.7%
1 terminated out of 6 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma